Monograph Capital

Fred Cohen serves as Partner and Chairman and sits on the firm's Investment Committee. He co-founded the firm in 2021 after leading TPG's biotechnology venture efforts since 2001. The investment team includes partners Tim Funnell, Charles Conn, and Matt McAviney, all of whom carry advanced scientific or medical degrees and share decision-making authority through the Investment Committee.

Monograph combines long-standing relationships with pharmaceutical companies, deep academic networks—its principals include former UCSF professors and Oxford-trained pharmacologists—and a company-formation model where the firm itself creates new companies around promising science. Partners Fred Cohen and Tim Funnell spent their prior careers at TPG, Vida Ventures, Syncona, and Third Rock Ventures, each of which built deal-sourcing engines grounded in academic medical centers.

Monograph invests directly in portfolio companies as a lead or co-lead investor in venture-stage financings. There is no publicly available evidence that the firm makes fund commitments to outside managers. Its website, portfolio, and team biographies all describe a direct-investment, company-building strategy.

Monograph targets early-stage life sciences companies, typically at Series A and Series B. It co-led AviadoBio's Series A in November 2021, participated in Sudo Biosciences' Series B in December 2023, and co-led Nocion Therapeutics' Series B in February 2024. The firm also forms companies from inception—Ouro Medicines and Ascend Advanced Therapies were both founded by Monograph.

Monograph co-founded Ouro Medicines in partnership with GSK and co-led its Series A in December 2024 alongside TPG Life Sciences Innovations, NEA, and Norwest Venture Partners. In Q2 2026, Gilead Sciences signed a definitive agreement to acquire Ouro for up to $2.175 billion. Monograph's Jaideep Dudani served as founding CEO of Ouro.

Monograph's principals have individual ties to philanthropic and nonprofit governance—Charles Conn chairs Patagonia and was CEO of the Rhodes Trust, and Fred Cohen is a member of the National Academy of Medicine—but the firm does not disclose a dedicated philanthropic entity or foundation structure on its website.

Monograph actively co-invests with other specialist life sciences investors. It co-led deals with NEA (AviadoBio, 2021), co-led with Arkin Bio Capital (Nocion, 2024), participated alongside Enavate Sciences and TPG (Sudo, 2023), and co-led with 5AM Ventures and OrbiMed (Prolynx). The firm does not describe a formal co-investment program for LPs beyond its own fund structure.